AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan performs well in phase 3 trial

Betsy Goodfellow | September 22, 2023 | News story | Research and Development |  AstraZeneca, Daiichi Sankyo, Oncology, breast cancer, clinical trial 

AstraZeneca and Daiichi Sankyo have shared positive high-level results from the TROPION-Breast01 phase 3 trial, which showed datopotamab deruxtecan (Dato-DXd) demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.

The trial not only showed the significant improvement in PFS, but also a trend in improvement for the dual primary endpoint of overall survival (OS) compared to chemotherapy. Data for OS was not mature at the stage of interim analysis meaning the trial will continue to assess this.

The drug’s safety profile remained consistent with previous clinical trials for this indication, and no new safety signals were identified.

Advertisement

Susan Galbraith, executive vice president of oncology R&D at AstraZeneca, commented: “Today’s TROPION-Breast01 news is a significant development for patients with HR-positive, HER2-low or negative metastatic breast cancer whose tumours have become insensitive to endocrine therapy and who currently face poor outcomes. We are encouraged by these positive results.”

This data is expected to be published at an upcoming medical meeting and will be shared with the relevant health authorities.

Betsy Goodfellow

Related Content

Tezspire improves symptoms and tissue inflammation in phase 3 EoE trial

AstraZeneca and Amgen’s Tezspire (tezepelumab) has demonstrated significant improvements in tissue inflammation and swallowing symptoms …

Charity commits £800,000 to AI research into late breast cancer recurrence

Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …

Most advanced breast cancer patients treated in community settings, Phesi study finds

Most patients with advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer are treated in community settings …

The Gateway to Local Adoption Series

Latest content